Sunn mann

Forebyggende råd mot prostatakreft

Prostata

Pasientinformasjon

Mannlige kjønnsorgan

Kliniske kapitler

Håndboken

Norsk Elektronisk Legehåndbok

Disponerende faktorer

Fem ting du kan gjøre

Vil du vite mer?

Prostatakreft

--&gt; https://www.helsedirektoratet.no/retningslinjer/prostatakreft-handlingsprogram

Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av prostatakreft. Helsedirektoratet. Sist faglig oppdatert 27.01.2023. Siden besøkt 05.10.2023. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=22212078[uid]

Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology. 2012 Jan;60(1):59-74. doi: 10.1111/j.1365-2559.2011.04039.x. PMID: 22212078 

--&gt; https://kreftlex.no/Prostatakreft/Prosedyrefolder/UTREDNING/Utredning

Kreftlex. Utredning ved prostatakreft. Institutt for kreftgenetikk og informatikk, 2023. 

--&gt; https://www.kreftregisteret.no/Temasider/om-kreft/

Kreftregisteret. Kreft i Norge. Siden sist oppdatert 10.05.2023. 

--&gt; https://www.kreftregisteret.no/Generelt/Rapporter/Arsrapport-fra-kvalitetsregistrene/Arsrapport-fra-prostatacancerregisteret-/arsrapport-for-prostatakreft-2022/

Kreftregisteret. Årsrapport for prostatakreft 2022. Publisert 10. mai 2022. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=32708810[uid]

Brandão A, Paulo P, Teixeira MR. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Int J Mol Sci. 2020 Jul 16;21(14):5036. doi: 10.3390/ijms21145036. PMID: 32708810 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=22116601[uid]

Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol. 2012 Apr;30(2):143-8. doi: 10.1007/s00345-011-0801-1. Epub 2011 Nov 25. PMID: 22116601 

--&gt; https://uroweb.org/guidelines/prostate-cancer

European Association of Urology (EAU). Prostate Cancer. 2023 [cited 2023 7th October]. 

--&gt; https://www.helsedirektoratet.no/nasjonale-forlop/pakkeforlop-for-kreft-diagnoseveiledere/diagnoseveiledere/prostatakreft

Helsedirektoratet. Diagnoseveiledere. Prostatakreft. Sist faglig oppdatert 02. august 2018. Siden lest 07. oktober 2023. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=19921978[uid]

Carlsson S, Adolfsson J, Bratt O, et al. Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. Scand J Urol Nephrol. 2009;43(5):350-6. doi: 10.3109/00365590902916930. PMID: 19921978 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=30288918[uid]

Pinsky PF, Miller E, Prorok P, et al. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019 May;123(5):854-860. doi: 10.1111/bju.14580. Epub 2018 Nov 2. PMID: 30288918 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=35422134[uid]

Frånlund M, Månsson M, Godtman RA, et al. Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial. J Urol. 2022 Aug;208(2):292-300. doi: 10.1097/JU.0000000000002696. Epub 2022 Apr 15. PMID: 35422134 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=35226140[uid]

Würnschimmel C, Chandrasekar T, Hahn L, Esen T, Shariat SF, Tilki D. MRI as a screening tool for prostate cancer: current evidence and future challenges. World J Urol. 2023 Apr;41(4):921-928. doi: 10.1007/s00345-022-03947-y. Epub 2022 Feb 28. PMID: 35226140 

--&gt; https://www.legeforeningen.no/kloke-valg/til-helsepersonell/legeforeningens-anbefalinger/norsk-forening-for-allmennmedisin/ikke-male-psa-uten-forst-a-vurdere-risiko-og-indikasjon-ved-hjelp-av-anamnese-og-klinisk-undersokelse/

Legeforeningen. Gjør kloke valg. Norsk forening for allmennmedisin. Unngå å måle PSA uten først å vurdere risiko og indikasjon ved hjelp av anamnese og klinisk undersøkelse. Publisert 4. juli 2018. Siden besøkt 05.10.2023 

--&gt; https://metodebok.no/index.php?action=topic&amp;item=33685641064d4c8d02b2

Nasjonal brukerhåndbok i Medisinsk biokjemi. PSA, P. Sist endret 30.11.2021. Siden lest 13.10.2023. 

Aus G, Abbou CC, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546-51. 

--&gt; http://www.nejm.org/search?q=350:2239

Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level &lt;= 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=12394692[uid]

Gerstenbluth RE, Seftel AD, Hampel N, Oefelein MG, Resnick MI. The accuracy of the increased prostate specific antigen level (greater than or equal to 20 ng./ml.) in predicting prostate cancer: is biopsy always required? J Urol. 2002 Nov;168(5):1990-3. doi: 10.1016/S0022-5347(05)64279-6. PMID: 12394692 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=35540708[uid]

Hagens MJ, Fernandez Salamanca M, Padhani AR, van Leeuwen PJ, van der Poel HG, Schoots IG. Diagnostic Performance of a Magnetic Resonance Imaging-directed Targeted plus Regional Biopsy Approach in Prostate Cancer Diagnosis: A Systematic Review and Meta-analysis. Eur Urol Open Sci. 2022 May 2;40:95-103. doi: 10.1016/j.euros.2022.04.001. PMID: 35540708 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=28373135[uid]

Distler FA, Radtke JP, Bonekamp D, et al. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction. J Urol. 2017 Sep;198(3):575-582. doi: 10.1016/j.juro.2017.03.130. Epub 2017 Mar 31. PMID: 28373135 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=29724877[uid]

Østerø Í Jákupsstovu J, Brodersen J. Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer? BMJ. 2018 May 3;361:k1202. doi: 10.1136/bmj.k1202. PMID: 29724877 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=27987032[uid]

Pepdjonovic L, Tan GH, Huang S, Mann S, Frydenberg M, Moon D, Hanegbi U, Landau A, Snow R, Grummet J. Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis. World J Urol. 2017 Aug;35(8):1199-1203. doi: 10.1007/s00345-016-1985-1. Epub 2016 Dec 16. PMID: 27987032 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=35839791[uid]

Jacewicz M, Günzel K, Rud E, et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2022 Oct;22(10):1465-1471. doi: 10.1016/S1473-3099(22)00373-5. Epub 2022 Jul 12. PMID: 35839791 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=28935163[uid]

Faria R, Soares MO, Spackman E, et al. Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS). Eur Urol. 2018 Jan;73(1):23-30. doi: 10.1016/j.eururo.2017.08.018. Epub 2017 Sep 19. PMID: 28935163 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=34230616[uid]

Oerther B, Engel H, Bamberg F, Sigle A, Gratzke C, Benndorf M. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis. 2022 Feb;25(2):256-263. doi: 10.1038/s41391-021-00417-1. Epub 2021 Jul 6. PMID: 34230616 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=32614123[uid]

Tamada T, Kido A, Yamamoto A, Takeuchi M, Miyaji Y, Moriya T, Sone T. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1. J Magn Reson Imaging. 2021 Jan;53(1):283-291. doi: 10.1002/jmri.27283. Epub 2020 Jul 2. PMID: 32614123 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=25806763[uid]

Raabe NK, Normann M, Lilleby W. Lavdoserate brakyterapi ved lavgradig prostatakreft. Tidsskr Nor Legeforen 2015; 135: 548-52. pmid:25806763 

Raabe NK, Lilleby W, Tafjord G, Åstrøm L. Høydoserate brakyterapi ved prostatakreft i Norge. Tidsskr Nor Legeforen 2008; 128: 1275-8. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=28757301[uid]

Lardas M, Liew M, van den Bergh RC, et al. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017 Dec;72(6):869-885. doi: 10.1016/j.eururo.2017.06.035. Epub 2017 Jul 27. PMID: 28757301 

--&gt; https://www.europa-uomo.org/who-we-are/quality-of-life-2/the-euproms-study/

Europa UOMO. EUPROMS Quality of Life. 2023 [cited 2023 08 October] 

Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004; 96: 1358-67. 

--&gt; http://dx.doi.org/10.1136/bmj.i851

Wallis CJD, Mahar AL, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 2016; 352: i851. doi:10.1136/bmj.i851 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=35900763[uid]

Bagshaw HP, Arnow KD, Trickey AW et al. Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer. JAMA Netw Open. 2022 Jul 1;5(7):e2223025. PMID: 35900763. 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=31268539[uid]

Jayadevappa R, Chhatre S, Malkowicz B, et al. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer. JAMA Netw Open 2019; 2: e196562. pmid:31268539 

--&gt; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Search&amp;db=PubMed&amp;term=28841388[uid]

Baik SH, Kury FSP, McDonald CJ. Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer. J Clin Oncol. 2017. PMID: 28841388 